HER1-based vaccine: Simultaneous activation of humoral and cellular immune response

The human epidermal growth factor receptor 1 (HER1) is a tumor-associated antigen that has been validated as a clinical target for several passive, non-immune therapies currently approved for the treatment of epithelial tumors. HER1 is an oncogene that not only promotes tumor progression and surviva...

Full description

Saved in:
Bibliographic Details
Published inSeminars in oncology Vol. 45; no. 1-2; pp. 75 - 83
Main Authors Bergado Báez, Gretchen, Hernández Fernández, Diana R., Mazorra Herrera, Zaima, Sánchez Ramírez, Belinda
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2018
Subjects
cancer vaccine
HER1
immune response
cancer vaccine
immune response
HER1
Online AccessGet full text

Cover

Abstract The human epidermal growth factor receptor 1 (HER1) is a tumor-associated antigen that has been validated as a clinical target for several passive, non-immune therapies currently approved for the treatment of epithelial tumors. HER1 is an oncogene that not only promotes tumor progression and survival, but also immune escape. Its overexpression in some epithelial malignancies has been correlated with a poor prognosis. We developed an approach to target HER1 by specific active immunotherapy, recognizing the extracellular domain of the receptor, using a combination of VSSP and Montanide ISA 51 as adjuvants. We summarize the results obtained with this vaccine in both the preclinical and clinical settings, emphasizing the importance of the induction of both humoral and cellular responses for the success of cancer vaccines as safe therapeutic alternatives for the treatment of cancer.
AbstractList The human epidermal growth factor receptor 1 (HER1) is a tumor-associated antigen that has been validated as a clinical target for several passive, non-immune therapies currently approved for the treatment of epithelial tumors. HER1 is an oncogene that not only promotes tumor progression and survival, but also immune escape. Its overexpression in some epithelial malignancies has been correlated with a poor prognosis. We developed an approach to target HER1 by specific active immunotherapy, recognizing the extracellular domain of the receptor, using a combination of VSSP and Montanide ISA 51 as adjuvants. We summarize the results obtained with this vaccine in both the preclinical and clinical settings, emphasizing the importance of the induction of both humoral and cellular responses for the success of cancer vaccines as safe therapeutic alternatives for the treatment of cancer.
Author Hernández Fernández, Diana R.
Sánchez Ramírez, Belinda
Mazorra Herrera, Zaima
Bergado Báez, Gretchen
Author_xml – sequence: 1
  givenname: Gretchen
  surname: Bergado Báez
  fullname: Bergado Báez, Gretchen
  organization: Tumor Immunology Direction, Center of Molecular Immunology, La Habana, Cuba
– sequence: 2
  givenname: Diana R.
  surname: Hernández Fernández
  fullname: Hernández Fernández, Diana R.
  organization: Tumor Immunology Direction, Center of Molecular Immunology, La Habana, Cuba
– sequence: 3
  givenname: Zaima
  surname: Mazorra Herrera
  fullname: Mazorra Herrera, Zaima
  organization: Clinical Direction, Center of Molecular Immunology, La Habana, Cuba
– sequence: 4
  givenname: Belinda
  surname: Sánchez Ramírez
  fullname: Sánchez Ramírez, Belinda
  email: belinda@cim.sld.cu
  organization: Tumor Immunology Direction, Center of Molecular Immunology, La Habana, Cuba
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30318087$$D View this record in MEDLINE/PubMed
BookMark eNqFkEtLxDAQgIMouq7-BcnRS-skbZrWm4ovEARXzyFNZjFLm6xJu-C_t8v6OHqZgeGb13dM9n3wSAhlkDMQxcUqT9i7qWhCl3NgdQ4iB-B7ZMZEwbNaQr1PZgBNkUkpyiNynNJqApjk_JAcFVCwGmo5I4uH2xeWtTqhpRttjPN4SReuH7tBewxjotoMbqMHFzwNS_o-9iHqjmpvqcGuGzsdqev70SONmNbBJzwhB0vdJTz9znPydnf7evOQPT3fP95cPWWm5OWQ2QpszcxSG5C1aC0Ia61pBGdFJYWUrCpsyUTb8mobSxQlMCMbjrYFXopiTs53c9cxfIyYBtW7tD1qd7nijAMH0VTNhNY71MSQUsSlWkfX6_ipGKitUrVSf0rVVqkCoSZjU-vZ95ax7dH-Nv44nIDrHYDTrxuHUSXj0Bu0LqIZlA3u_y1fZfiOog
CitedBy_id crossref_primary_10_1016_j_celrep_2020_107679
crossref_primary_10_29328_journal_acst_1001029
crossref_primary_10_1089_jir_2023_0141
crossref_primary_10_3389_fbioe_2024_1335898
crossref_primary_10_1007_s13402_022_00700_w
crossref_primary_10_1016_j_pharmthera_2021_108106
Cites_doi 10.18632/oncotarget.4145
10.1016/j.neo.2017.11.001
10.1038/nrm1962
10.1038/srep31740
10.1517/14728214.13.2.295
10.18632/oncotarget.19925
10.1371/journal.pmed.0040315
10.1002/jgm.2606
10.1158/2326-6066.CIR-14-0110
10.2741/3612
10.1016/S1380-2933(97)00065-1
10.1186/s12885-016-2201-9
10.1080/14737140.2017.1355243
10.1007/s00262-017-2068-x
10.2217/imt.14.22
10.1007/s10637-010-9619-8
10.1002/jcp.10411
10.1016/S1535-6108(04)00083-2
10.1016/S0014-4827(02)00101-5
10.1073/pnas.0913476107
10.1016/B978-0-12-407190-2.00007-1
10.1056/NEJMoa1209124
10.1358/dot.2005.41.2.882662
10.1007/s10549-016-3751-x
10.1038/nrc.2017.84
10.1056/NEJMoa0910383
10.1080/21645515.2015.1071455
10.3389/fphar.2017.00263
10.1371/journal.pone.0015945
10.1056/NEJMoa1713137
10.1200/JCO.2006.08.1620
10.3389/fimmu.2014.00520
10.1038/nrc1609
10.1517/14728222.2011.648617
10.7150/jca.20059
10.1056/NEJMoa1001294
10.1038/s41598-017-10925-7
10.1074/jbc.M207135200
10.1056/NEJMoa050753
10.3389/fphar.2017.00595
10.4161/hv.29604
10.1002/ijc.22085
10.1016/j.vaccine.2012.10.098
10.1016/S0092-8674(02)00963-7
10.1016/S1533-0028(11)70161-X
10.1007/s00262-008-0540-3
10.1016/S0092-8674(02)00940-6
10.1093/annonc/mdh011
10.1093/annonc/mdw214
10.1093/intimm/dxw015
10.1016/j.critrevonc.2006.12.008
10.1593/neo.131584
10.1158/1078-0432.CCR-15-0855
10.1158/2326-6066.CIR-16-0177
10.1038/nrc3309
10.1158/0008-5472.SABCS-09-5089
10.1158/0008-5472.226.65.1
10.1158/1078-0432.CCR-12-2426
10.4161/hv.29847
10.1172/JCI32278
10.4161/cbt.9.5.10981
10.1056/NEJMoa1513750
10.1080/01926230701320337
10.1038/sj.bjc.6601536
10.1158/1078-0432.CCR-07-1448
10.1016/j.vaccine.2004.02.010
10.1377/hlthaff.28.1.160
10.1007/s00262-012-1330-5
10.4049/jimmunol.1003477
10.1634/theoncologist.8-4-303
10.1038/35052073
10.1016/S1525-7304(11)70747-1
10.1093/annonc/mdx016
10.4161/hv.19795
10.1056/NEJMoa1703643
10.1016/j.critrevonc.2017.02.026
10.1038/nature01392
10.1056/NEJMoa071834
10.1056/NEJMra0707704
10.1093/annonc/mdt133
10.1111/j.1742-481X.2012.01074.x
10.4161/hv.20740
10.1007/978-1-4939-0345-0_39
10.1038/onc.2015.372
10.4161/21645515.2014.973317
10.1158/1078-0432.CCR-07-1050
10.18632/oncotarget.11413
10.3389/fphar.2017.00382
10.1016/j.vaccine.2008.07.018
10.1002/cncr.21643
10.1634/theoncologist.2010-0298
10.1200/JCO.2016.69.7748
10.1586/14760584.4.3.259
10.1158/0008-5472.CAN-09-1417
10.1016/j.ccr.2005.03.003
ContentType Journal Article
Copyright 2018 The Authors
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2018 The Authors
– notice: Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
DBID 6I.
AAFTH
NPM
AAYXX
CITATION
7X8
DOI 10.1053/j.seminoncol.2018.05.002
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1532-8708
EndPage 83
ExternalDocumentID 10_1053_j_seminoncol_2018_05_002
30318087
S0093775418300447
Genre Journal Article
Review
GroupedDBID ---
--K
.1-
.55
.FO
.GJ
0R~
123
1P~
3O-
4.4
457
4CK
53G
5RE
6I.
AAEDW
AAFTH
AALRI
AAQQT
AAQXK
AAWTL
AAXUO
ABFRF
ABJNI
ABOCM
ABUDA
ACGFO
ADBBV
ADMUD
AEFWE
AENEX
AEVXI
AFCTW
AFFNX
AFRHN
AFTJW
AGHFR
AGRDE
AHPSJ
AITUG
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ASPBG
AVWKF
AZFZN
CS3
DU5
EBS
EJD
F5P
FDB
FEDTE
FGOYB
GBLVA
HVGLF
HZ~
IH2
J5H
K-O
L7B
MJL
N4W
O9-
OC~
OO-
P2P
R2-
RIG
ROL
SEL
SES
SJN
TWZ
UDS
X7M
Z5R
ZGI
ZXP
AAQOH
AFETI
AFJKZ
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c424t-d60d81cfac0785bd05dddc9521367577163d415bb2615bb4e5401c792edb02453
ISSN 0093-7754
IngestDate Fri Oct 25 10:47:21 EDT 2024
Thu Sep 26 18:40:32 EDT 2024
Wed Oct 16 00:58:57 EDT 2024
Fri Feb 23 02:26:47 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1-2
Keywords cancer vaccine
immune response
HER1
Language English
License This is an open access article under the CC BY-NC-ND license.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c424t-d60d81cfac0785bd05dddc9521367577163d415bb2615bb4e5401c792edb02453
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
OpenAccessLink https://dx.doi.org/10.1053/j.seminoncol.2018.05.002
PMID 30318087
PQID 2120205969
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_2120205969
crossref_primary_10_1053_j_seminoncol_2018_05_002
pubmed_primary_30318087
elsevier_sciencedirect_doi_10_1053_j_seminoncol_2018_05_002
PublicationCentury 2000
PublicationDate January 2018
2018-01-00
20180101
PublicationDateYYYYMMDD 2018-01-01
PublicationDate_xml – month: 01
  year: 2018
  text: January 2018
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Seminars in oncology
PublicationTitleAlternate Semin Oncol
PublicationYear 2018
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Citri, Yarden (bib0009) 2006; 7
Pedersen, Jacobsen, Koefoed (bib0069) 2010; 70
Ogiso, Ishitani, Nureki (bib0011) 2002; 110
Dong, Lei, Zhang (bib0029) 2017; 8
Specenier, Vermorken (bib0037) 2013; 7
Maung, Nemunaitis, Cunningham (bib0092) 2001; 3
Rotow, Bivona (bib0027) 2017; 17
Coveler, Bates, Disis (bib0081) 2010; 2
Curigliano, Goldhirsch (bib0104) 2017; 28
Gardner, Elzey, Hahn (bib0078) 2012; 8
Mesa, De Leon J, Fernandez (bib0060) 2004; 22
Mazorra, Lavastida, Concha-Benavente (bib0036) 2017; 8
Lenz (bib0034) 2006; 20
Dassonville, Bozec, Fischel, Milano (bib0024) 2007; 62
Seshacharyulu, Ponnusamy, Haridas, Jain, Ganti, Batra (bib0003) 2012; 16
Thakur, Wozniak (bib0032) 2017; 8
Shepherd, Rodrigues Pereira, Ciuleanu (bib0040) 2005; 353
Sánchez-Ramírez, Aguiar, Hernández (bib0062) 2008; 26
Vidarsson, Dekkers, Rispens (bib0087) 2014; 5
Schneider, Yarden (bib0016) 2016; 35
Citri, Skaria, Yarden (bib0015) 2003; 284
Tyagi (bib0031) 2005; 5
Finn (bib0080) 2014; 2
Lohmueller, Sato, Popova (bib0105) 2016; 6
Park, Liu, Yee (bib0042) 2016; 375
Costa, Halmos, Kumar (bib0066) 2007; 4
Li, Schmitz, Jeffrey (bib0064) 2005; 7
Hynes, Lane (bib0001) 2005; 5
Garrido, Rabasa, Garrido (bib0054) 2017; 8
Pinto, Barone, Girolomoni (bib0083) 2011; 16
Lenz (bib0038) 2007; 1
Mateo, Moreno, Amour, Lombardero (bib0033) 1997; 3
Ciardiello, Tortora (bib0025) 2008; 358
Suda, Rivard, Mitsudomi, Hirsch (bib0028) 2017; 17
Sánchez-Ramírez, Aguiar, Hernández (bib0061) 2008; 26
Soria, Ohe, Vansteenkiste (bib0044) 2018; 378
Cho, Mason, Ramyar (bib0013) 2003; 421
Stamos, Sliwkowski, Eigenbrot (bib0008) 2002; 277
Amann, Kalyankrishna, Massion (bib0017) 2005; 65
Guardino, Cassidy, Pienkowski, Radulovik (bib0103) 2010; 69
Garrett, McKern, Lou (bib0063) 2002; 110
Srivastava, Lee, Andrade Filho (bib0035) 2013; 19
Yarden, Sliwkowski (bib0007) 2001; 2
Fernández A, Alvarez, Fernández, Lee, Mesa (bib0089) 2014; 10
Yarden, Pines (bib0002) 2012; 12
Selvaggi, Novello, Torri (bib0018) 2004; 15
Alpizar, Karwacz, Arce (bib0072) 2012; 14
Jonker, O'Callaghan, Karapetis (bib0046) 2007; 357
Podrazil, Horvath, Becht (bib0093) 2015; 6
Graff, Chamberlain (bib0095) 2015; 10
Tagliamonte, Petrizzo, Tornesello, Buonaguro, Buonaguro (bib0005) 2014; 10
Milani, Sangiolo, Montemurro, Aglietta, Valabrega (bib0057) 2013; 24
(bib0101) 2012; 8
Slamon, Eiermann, Robert (bib0050) 2011; 365
Campiglio, Locatelli, Olgiati (bib0067) 2004; 198
Cameron (bib0043) 2007; 5
Elmore (bib0065) 2007; 35
Virnig, Baxter, Habermann, Feldman, Bradley (bib0071) 2009; 28
Zhang, Li, Wang (bib0023) 2017; 7
Fishman (bib0006) 2014; 1139
Zhang, Nie, Chakrabarty (bib0022) 2010; 15
Garrido, Rabasa, Sanchez (bib0074) 2011; 187
Sandler (bib0082) 2006; 20
Bada Barro, Iglesias, León (bib0085) 2012; 31
van Doorn E, Huckriede, Hak (bib0086) 2016; 12
Zhang, Berezov, Wang (bib0012) 2007; 117
Hernes, Fossa, Berner, Otnes, Nesland (bib0075) 2004; 90
Mittendorf, Holmes, Ponniah, Peoples (bib0097) 2008; 57
Santegoets, Stam, Lougheed (bib0091) 2013; 62
Guo, Manjili, Subjeck (bib0055) 2013; 119
Bossi, Resteghini, Paielli (bib0019) 2016; 7
Baxter (bib0088) 2014; 10
Di Lorenzo, Tortora, D'Armiento (bib0020) 2002; 8
Temizoz, Kuroda, Ishii (bib0106) 2016; 28
Rodriguez, Rivero, del Castillo Bahi (bib0004) 2010; 9
Kantoff, Higano, Shore (bib0079) 2010; 363
Bseiso, Lev-Cohain, Gross, Grozinsky-Glasberg (bib0045) 2016; 2016
Brea, Oh, Manchado (bib0021) 2016; 4
Van Cutsem E, Siena (bib0047) 2007; 25
Iida, Brand, Starr (bib0070) 2013; 15
Nemunaitis (bib0090) 2005; 4
Gavilondo, Hernandez-Bernal, Ayala-Avila (bib0100) 2014; 32
Schneble, Berry, Trappey (bib0096) 2014; 6
Rodriguez, Popa, Martinez (bib0099) 2016; 22
Caballero, Aira, Lavastida (bib0058) 2017; 8
Peoples, Holmes, Hueman (bib0098) 2008; 14
Krall, Beyer, MacBeath (bib0010) 2011; 6
Strumberg, Schultheis, Scheulen (bib0049) 2012; 30
Kantoff, Gulley, Pico-Navarro (bib0102) 2017; 35
Paz-Ares, Socinski, Shahidi (bib0048) 2016; 27
Sanchez-Ramırez, Suarez, Garrido (bib0059) 2006; 119
Emens (bib0056) 2008; 13
Verma, Miles, Gianni (bib0051) 2012; 367
Limentani, Campone, Dorval (bib0084) 2016; 156
Ye, Qian, Jin, Qian (bib0107) 2018; 9
Franklin, Carey, Vajdos (bib0014) 2004; 5
Oronsky, Ma, Reid (bib0026) 2018; 20
Spangler, Neil, Abramovitch (bib0068) 2010; 107
Fucikova, Podrazil, Jarolim (bib0094) 2018; 67
Fuentes, Chacon, Casaco (bib0073) 2014; 11
Lee, Leung, Choy (bib0041) 2016; 16
Vickers AJ, Bianco FJ Jr, Boorjian S, Scardino PT, Eastham JA. Does a delay between diagnosis and radical prostatectomy increase the risk of disease recurrence? Cancer 2006;106:576-580.
Cohen, Williams, Sridhara, Chen, Pazdur (bib0039) 2003; 8
von Minckwitz, Procter, de Azambuja (bib0052) 2017; 377
Garcia, Neninger, Torre (bib0053) 2008; 14
Harding, Burtness (bib0030) 2005; 41
Maia, Hansen (bib0077) 2017; 113
Elmore (10.1053/j.seminoncol.2018.05.002_bib0065) 2007; 35
Santegoets (10.1053/j.seminoncol.2018.05.002_bib0091) 2013; 62
Mittendorf (10.1053/j.seminoncol.2018.05.002_bib0097) 2008; 57
Verma (10.1053/j.seminoncol.2018.05.002_bib0051) 2012; 367
Guardino (10.1053/j.seminoncol.2018.05.002_bib0103) 2010; 69
Brea (10.1053/j.seminoncol.2018.05.002_bib0021) 2016; 4
Guo (10.1053/j.seminoncol.2018.05.002_bib0055) 2013; 119
van Doorn E (10.1053/j.seminoncol.2018.05.002_bib0086) 2016; 12
Cho (10.1053/j.seminoncol.2018.05.002_bib0013) 2003; 421
Lohmueller (10.1053/j.seminoncol.2018.05.002_bib0105) 2016; 6
Garrett (10.1053/j.seminoncol.2018.05.002_bib0063) 2002; 110
Graff (10.1053/j.seminoncol.2018.05.002_bib0095) 2015; 10
Garcia (10.1053/j.seminoncol.2018.05.002_bib0053) 2008; 14
Finn (10.1053/j.seminoncol.2018.05.002_bib0080) 2014; 2
Vidarsson (10.1053/j.seminoncol.2018.05.002_bib0087) 2014; 5
Alpizar (10.1053/j.seminoncol.2018.05.002_bib0072) 2012; 14
Gavilondo (10.1053/j.seminoncol.2018.05.002_bib0100) 2014; 32
Emens (10.1053/j.seminoncol.2018.05.002_bib0056) 2008; 13
Srivastava (10.1053/j.seminoncol.2018.05.002_bib0035) 2013; 19
Costa (10.1053/j.seminoncol.2018.05.002_bib0066) 2007; 4
Mateo (10.1053/j.seminoncol.2018.05.002_bib0033) 1997; 3
Van Cutsem E (10.1053/j.seminoncol.2018.05.002_bib0047) 2007; 25
Maung (10.1053/j.seminoncol.2018.05.002_bib0092) 2001; 3
Coveler (10.1053/j.seminoncol.2018.05.002_bib0081) 2010; 2
Ye (10.1053/j.seminoncol.2018.05.002_bib0107) 2018; 9
Dong (10.1053/j.seminoncol.2018.05.002_bib0029) 2017; 8
Tagliamonte (10.1053/j.seminoncol.2018.05.002_bib0005) 2014; 10
Gardner (10.1053/j.seminoncol.2018.05.002_bib0078) 2012; 8
Suda (10.1053/j.seminoncol.2018.05.002_bib0028) 2017; 17
Lenz (10.1053/j.seminoncol.2018.05.002_bib0038) 2007; 1
Baxter (10.1053/j.seminoncol.2018.05.002_bib0088) 2014; 10
Milani (10.1053/j.seminoncol.2018.05.002_bib0057) 2013; 24
Sánchez-Ramírez (10.1053/j.seminoncol.2018.05.002_bib0062) 2008; 26
Tyagi (10.1053/j.seminoncol.2018.05.002_bib0031) 2005; 5
Dassonville (10.1053/j.seminoncol.2018.05.002_bib0024) 2007; 62
Campiglio (10.1053/j.seminoncol.2018.05.002_bib0067) 2004; 198
Nemunaitis (10.1053/j.seminoncol.2018.05.002_bib0090) 2005; 4
Ogiso (10.1053/j.seminoncol.2018.05.002_bib0011) 2002; 110
Hernes (10.1053/j.seminoncol.2018.05.002_bib0075) 2004; 90
Rodriguez (10.1053/j.seminoncol.2018.05.002_bib0004) 2010; 9
Li (10.1053/j.seminoncol.2018.05.002_bib0064) 2005; 7
Hynes (10.1053/j.seminoncol.2018.05.002_bib0001) 2005; 5
Soria (10.1053/j.seminoncol.2018.05.002_bib0044) 2018; 378
Bada Barro (10.1053/j.seminoncol.2018.05.002_bib0085) 2012; 31
Lee (10.1053/j.seminoncol.2018.05.002_bib0041) 2016; 16
Fucikova (10.1053/j.seminoncol.2018.05.002_bib0094) 2018; 67
Fuentes (10.1053/j.seminoncol.2018.05.002_bib0073) 2014; 11
Yarden (10.1053/j.seminoncol.2018.05.002_bib0002) 2012; 12
Caballero (10.1053/j.seminoncol.2018.05.002_bib0058) 2017; 8
Oronsky (10.1053/j.seminoncol.2018.05.002_bib0026) 2018; 20
Shepherd (10.1053/j.seminoncol.2018.05.002_bib0040) 2005; 353
Jonker (10.1053/j.seminoncol.2018.05.002_bib0046) 2007; 357
Citri (10.1053/j.seminoncol.2018.05.002_bib0009) 2006; 7
(10.1053/j.seminoncol.2018.05.002_bib0101) 2012; 8
Limentani (10.1053/j.seminoncol.2018.05.002_bib0084) 2016; 156
Garrido (10.1053/j.seminoncol.2018.05.002_bib0054) 2017; 8
Amann (10.1053/j.seminoncol.2018.05.002_bib0017) 2005; 65
Bossi (10.1053/j.seminoncol.2018.05.002_bib0019) 2016; 7
Schneider (10.1053/j.seminoncol.2018.05.002_bib0016) 2016; 35
Rotow (10.1053/j.seminoncol.2018.05.002_bib0027) 2017; 17
Rodriguez (10.1053/j.seminoncol.2018.05.002_bib0099) 2016; 22
Pedersen (10.1053/j.seminoncol.2018.05.002_bib0069) 2010; 70
Specenier (10.1053/j.seminoncol.2018.05.002_bib0037) 2013; 7
Cohen (10.1053/j.seminoncol.2018.05.002_bib0039) 2003; 8
10.1053/j.seminoncol.2018.05.002_bib0076
Seshacharyulu (10.1053/j.seminoncol.2018.05.002_bib0003) 2012; 16
Selvaggi (10.1053/j.seminoncol.2018.05.002_bib0018) 2004; 15
Virnig (10.1053/j.seminoncol.2018.05.002_bib0071) 2009; 28
Di Lorenzo (10.1053/j.seminoncol.2018.05.002_bib0020) 2002; 8
Zhang (10.1053/j.seminoncol.2018.05.002_bib0012) 2007; 117
Schneble (10.1053/j.seminoncol.2018.05.002_bib0096) 2014; 6
Spangler (10.1053/j.seminoncol.2018.05.002_bib0068) 2010; 107
Sánchez-Ramírez (10.1053/j.seminoncol.2018.05.002_bib0061) 2008; 26
Kantoff (10.1053/j.seminoncol.2018.05.002_bib0102) 2017; 35
Pinto (10.1053/j.seminoncol.2018.05.002_bib0083) 2011; 16
Sanchez-Ramırez (10.1053/j.seminoncol.2018.05.002_bib0059) 2006; 119
Temizoz (10.1053/j.seminoncol.2018.05.002_bib0106) 2016; 28
Franklin (10.1053/j.seminoncol.2018.05.002_bib0014) 2004; 5
Yarden (10.1053/j.seminoncol.2018.05.002_bib0007) 2001; 2
Mazorra (10.1053/j.seminoncol.2018.05.002_bib0036) 2017; 8
Iida (10.1053/j.seminoncol.2018.05.002_bib0070) 2013; 15
Paz-Ares (10.1053/j.seminoncol.2018.05.002_bib0048) 2016; 27
Fishman (10.1053/j.seminoncol.2018.05.002_bib0006) 2014; 1139
Krall (10.1053/j.seminoncol.2018.05.002_bib0010) 2011; 6
Kantoff (10.1053/j.seminoncol.2018.05.002_bib0079) 2010; 363
Garrido (10.1053/j.seminoncol.2018.05.002_bib0074) 2011; 187
Fernández A (10.1053/j.seminoncol.2018.05.002_bib0089) 2014; 10
Sandler (10.1053/j.seminoncol.2018.05.002_bib0082) 2006; 20
Lenz (10.1053/j.seminoncol.2018.05.002_bib0034) 2006; 20
Park (10.1053/j.seminoncol.2018.05.002_bib0042) 2016; 375
Thakur (10.1053/j.seminoncol.2018.05.002_bib0032) 2017; 8
von Minckwitz (10.1053/j.seminoncol.2018.05.002_bib0052) 2017; 377
Citri (10.1053/j.seminoncol.2018.05.002_bib0015) 2003; 284
Stamos (10.1053/j.seminoncol.2018.05.002_bib0008) 2002; 277
Mesa (10.1053/j.seminoncol.2018.05.002_bib0060) 2004; 22
Zhang (10.1053/j.seminoncol.2018.05.002_bib0023) 2017; 7
Ciardiello (10.1053/j.seminoncol.2018.05.002_bib0025) 2008; 358
Maia (10.1053/j.seminoncol.2018.05.002_bib0077) 2017; 113
Bseiso (10.1053/j.seminoncol.2018.05.002_bib0045) 2016; 2016
Zhang (10.1053/j.seminoncol.2018.05.002_bib0022) 2010; 15
Cameron (10.1053/j.seminoncol.2018.05.002_bib0043) 2007; 5
Harding (10.1053/j.seminoncol.2018.05.002_bib0030) 2005; 41
Curigliano (10.1053/j.seminoncol.2018.05.002_bib0104) 2017; 28
Strumberg (10.1053/j.seminoncol.2018.05.002_bib0049) 2012; 30
Slamon (10.1053/j.seminoncol.2018.05.002_bib0050) 2011; 365
Podrazil (10.1053/j.seminoncol.2018.05.002_bib0093) 2015; 6
Peoples (10.1053/j.seminoncol.2018.05.002_bib0098) 2008; 14
References_xml – volume: 35
  start-page: 495
  year: 2007
  end-page: 516
  ident: bib0065
  article-title: Apoptosis: a review of programmed cell death
  publication-title: Toxicol Pathol
  contributor:
    fullname: Elmore
– volume: 284
  start-page: 54
  year: 2003
  end-page: 65
  ident: bib0015
  article-title: The deaf and the dumb: the biology of ErbB-2 and ErbB-3
  publication-title: Exp Cell Res
  contributor:
    fullname: Yarden
– volume: 14
  start-page: 840
  year: 2008
  end-page: 846
  ident: bib0053
  article-title: Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine
  publication-title: Clin Cancer Res
  contributor:
    fullname: Torre
– volume: 119
  start-page: 2190
  year: 2006
  end-page: 2199
  ident: bib0059
  article-title: Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant
  publication-title: Int J Cancer
  contributor:
    fullname: Garrido
– volume: 41
  start-page: 107
  year: 2005
  end-page: 127
  ident: bib0030
  article-title: Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody
  publication-title: Drugs Today (Barc)
  contributor:
    fullname: Burtness
– volume: 28
  start-page: 441
  year: 2017
  end-page: 443
  ident: bib0104
  article-title: Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection
  publication-title: Ann Oncol
  contributor:
    fullname: Goldhirsch
– volume: 35
  start-page: 124
  year: 2017
  end-page: 125
  ident: bib0102
  article-title: Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of PROSTVAC in men with metastatic castration-resistant prostate cancer
  publication-title: J Clin Oncol
  contributor:
    fullname: Pico-Navarro
– volume: 8
  start-page: 263
  year: 2017
  ident: bib0058
  article-title: Safety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: a dose-escalation phase I study trial
  publication-title: Front Pharmacol
  contributor:
    fullname: Lavastida
– volume: 2
  start-page: 25
  year: 2010
  end-page: 36
  ident: bib0081
  article-title: Progress in the development of a therapeutic vaccine for breast cancer
  publication-title: Breast Cancer
  contributor:
    fullname: Disis
– volume: 15
  start-page: 28
  year: 2004
  end-page: 32
  ident: bib0018
  article-title: Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer
  publication-title: Ann Oncol
  contributor:
    fullname: Torri
– volume: 65
  start-page: 226
  year: 2005
  end-page: 235
  ident: bib0017
  article-title: Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer
  publication-title: Cancer Res
  contributor:
    fullname: Massion
– volume: 16
  start-page: 147
  year: 2016
  ident: bib0041
  article-title: Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib
  publication-title: BMC Cancer
  contributor:
    fullname: Choy
– volume: 8
  start-page: 3438
  year: 2002
  end-page: 3444
  ident: bib0020
  article-title: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
  publication-title: Clin Cancer Res
  contributor:
    fullname: D'Armiento
– volume: 12
  start-page: 159
  year: 2016
  end-page: 169
  ident: bib0086
  article-title: Safety and tolerability evaluation of the use of Montanide ISA51 as vaccine adjuvant: a systematic review
  publication-title: Hum Vaccin Immunother
  contributor:
    fullname: Hak
– volume: 27
  start-page: 1573
  year: 2016
  end-page: 1579
  ident: bib0048
  article-title: Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer
  publication-title: Ann Oncol
  contributor:
    fullname: Shahidi
– volume: 69
  start-page: 5089
  year: 2010
  ident: bib0103
  article-title: Results of two phase I clinical trials of MVA-BN-HER2 in HER-2 overexpressing metastatic breast cancer patients
  publication-title: Cancer Res
  contributor:
    fullname: Radulovik
– volume: 20
  start-page: 35
  year: 2006
  end-page: 40
  ident: bib0082
  article-title: Nondermatologic adverse events associated with anti-EGFR therapy
  publication-title: Oncology
  contributor:
    fullname: Sandler
– volume: 3
  start-page: 25
  year: 2001
  end-page: 26
  ident: bib0092
  article-title: Granulocyte macrophage colony-stimulating factor (GM-CSF) gene-transduced tumor vaccines (GVAX) in non-small-cell lung cancer
  publication-title: Clinical Lung Cancer
  contributor:
    fullname: Cunningham
– volume: 57
  start-page: 1511
  year: 2008
  end-page: 1521
  ident: bib0097
  article-title: The E75 HER2/neu peptide vaccine
  publication-title: Cancer Immunol Immunother
  contributor:
    fullname: Peoples
– volume: 6
  start-page: 519
  year: 2014
  end-page: 531
  ident: bib0096
  article-title: The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response
  publication-title: Immunotherapy
  contributor:
    fullname: Trappey
– volume: 375
  start-page: 11
  year: 2016
  end-page: 22
  ident: bib0042
  article-title: Adaptive randomization of Neratinib in early breast cancer
  publication-title: N Engl J Med
  contributor:
    fullname: Yee
– volume: 67
  start-page: 89
  year: 2018
  end-page: 100
  ident: bib0094
  article-title: Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer
  publication-title: Cancer Immunol Immunother
  contributor:
    fullname: Jarolim
– volume: 6
  start-page: e15945
  year: 2011
  ident: bib0010
  article-title: High- and low-affinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways
  publication-title: PloS One
  contributor:
    fullname: MacBeath
– volume: 15
  start-page: 151
  year: 2010
  end-page: 165
  ident: bib0022
  article-title: Growth factors in tumor microenvironment
  publication-title: Front Biosci
  contributor:
    fullname: Chakrabarty
– volume: 358
  start-page: 1160
  year: 2008
  end-page: 1174
  ident: bib0025
  article-title: EGFR antagonists in cancer treatment
  publication-title: N Engl J Med
  contributor:
    fullname: Tortora
– volume: 22
  start-page: 3782
  year: 2016
  end-page: 3790
  ident: bib0099
  article-title: A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients
  publication-title: Clin Cancer Res
  contributor:
    fullname: Martinez
– volume: 5
  start-page: 341
  year: 2005
  end-page: 354
  ident: bib0001
  article-title: ERBB receptors and cancer: the complexity of targeted inhibitors
  publication-title: Nat Rev Cancer
  contributor:
    fullname: Lane
– volume: 377
  start-page: 122
  year: 2017
  end-page: 131
  ident: bib0052
  article-title: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
  publication-title: N Engl J Med
  contributor:
    fullname: de Azambuja
– volume: 16
  start-page: 15
  year: 2012
  end-page: 31
  ident: bib0003
  article-title: Targeting the EGFR signaling pathway in cancer therapy
  publication-title: Expert Opin Ther Targets
  contributor:
    fullname: Batra
– volume: 2016
  year: 2016
  ident: bib0045
  article-title: Vandetanib induces a marked anti-tumor effect and amelioration of ectopic Cushing's syndrome in a medullary thyroid carcinoma patient
  publication-title: Endocrinol Diabetes Metab Case Rep
  contributor:
    fullname: Grozinsky-Glasberg
– volume: 17
  start-page: 779
  year: 2017
  end-page: 786
  ident: bib0028
  article-title: Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms
  publication-title: Exp Rev Anticancer Ther
  contributor:
    fullname: Hirsch
– volume: 31
  start-page: 89
  year: 2012
  end-page: 95
  ident: bib0085
  article-title: Non-clinical immuno-toxicological evaluation of HER1 cancer vaccine in non-human primates: a 12-month study
  publication-title: Vaccine
  contributor:
    fullname: León
– volume: 3
  start-page: 71
  year: 1997
  end-page: 81
  ident: bib0033
  article-title: Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity
  publication-title: Immunotechnology
  contributor:
    fullname: Lombardero
– volume: 363
  start-page: 411
  year: 2010
  end-page: 422
  ident: bib0079
  article-title: Sipuleucel-T immunotherapy for castration-resistant prostate cancer
  publication-title: N Engl J Med
  contributor:
    fullname: Shore
– volume: 35
  start-page: 2949
  year: 2016
  end-page: 2960
  ident: bib0016
  article-title: The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors
  publication-title: Oncogene
  contributor:
    fullname: Yarden
– volume: 62
  start-page: 53
  year: 2007
  end-page: 61
  ident: bib0024
  article-title: EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences
  publication-title: Crit Rev Oncol Hematol
  contributor:
    fullname: Milano
– volume: 10
  start-page: 1
  year: 2015
  end-page: 10
  ident: bib0095
  article-title: Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy
  publication-title: Core Evidence
  contributor:
    fullname: Chamberlain
– volume: 198
  start-page: 259
  year: 2004
  end-page: 268
  ident: bib0067
  article-title: Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level
  publication-title: J Cell Physiol
  contributor:
    fullname: Olgiati
– volume: 119
  start-page: 421
  year: 2013
  end-page: 4275
  ident: bib0055
  article-title: Therapeutic cancer vaccines: past, present, and future
  publication-title: Adv Cancer Res
  contributor:
    fullname: Subjeck
– volume: 5
  start-page: 456
  year: 2007
  end-page: 458
  ident: bib0043
  article-title: Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer
  publication-title: Clin Adv Hematol Oncol
  contributor:
    fullname: Cameron
– volume: 28
  start-page: 160
  year: 2009
  end-page: 168
  ident: bib0071
  article-title: A matter of race: early-versus late-stage cancer diagnosis
  publication-title: Health Affairs
  contributor:
    fullname: Bradley
– volume: 110
  start-page: 763
  year: 2002
  end-page: 773
  ident: bib0063
  article-title: Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha
  publication-title: Cell
  contributor:
    fullname: Lou
– volume: 16
  start-page: 228
  year: 2011
  end-page: 238
  ident: bib0083
  article-title: Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy
  publication-title: Oncologist
  contributor:
    fullname: Girolomoni
– volume: 26
  start-page: 4918
  year: 2008
  end-page: 4926
  ident: bib0062
  article-title: Anti-EGFR activation, anti-proliferative and pro-apoptotic effects of polyclonal antibodies induced by EGFR-based cancer vaccine
  publication-title: Vaccine
  contributor:
    fullname: Hernández
– volume: 7
  start-page: 301
  year: 2005
  end-page: 311
  ident: bib0064
  article-title: Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
  publication-title: Cancer Cell
  contributor:
    fullname: Jeffrey
– volume: 17
  start-page: 637
  year: 2017
  end-page: 658
  ident: bib0027
  article-title: Understanding and targeting resistance mechanisms in NSCLC
  publication-title: Nat Rev Cancer
  contributor:
    fullname: Bivona
– volume: 8
  start-page: 64600
  year: 2017
  end-page: 64606
  ident: bib0029
  article-title: Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
  publication-title: Oncotarget
  contributor:
    fullname: Zhang
– volume: 2
  start-page: 127
  year: 2001
  end-page: 137
  ident: bib0007
  article-title: Untangling the ErbB signalling network
  publication-title: Nat Rev Mol Cell Biol
  contributor:
    fullname: Sliwkowski
– volume: 8
  start-page: 1156
  year: 2012
  end-page: 1160
  ident: bib0101
  article-title: Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer
  publication-title: Hum Vaccines Immunother
– volume: 378
  start-page: 113
  year: 2018
  end-page: 125
  ident: bib0044
  article-title: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
  publication-title: N Engl J Med
  contributor:
    fullname: Vansteenkiste
– volume: 30
  start-page: 1138
  year: 2012
  end-page: 1143
  ident: bib0049
  article-title: Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
  publication-title: Invest New Drugs
  contributor:
    fullname: Scheulen
– volume: 367
  start-page: 1783
  year: 2012
  end-page: 1791
  ident: bib0051
  article-title: Trastuzumab emtansine for HER2-positive advanced breast cancer
  publication-title: N Engl J Med
  contributor:
    fullname: Gianni
– volume: 357
  start-page: 2040
  year: 2007
  end-page: 2048
  ident: bib0046
  article-title: Cetuximab for the treatment of colorectal cancer
  publication-title: N Engl J Med
  contributor:
    fullname: Karapetis
– volume: 32
  start-page: 2241
  year: 2014
  end-page: 2250
  ident: bib0100
  article-title: Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors
  publication-title: results of the CENTAURO antigen dose escalation phase I clinical trial. Vaccine
  contributor:
    fullname: Ayala-Avila
– volume: 8
  start-page: 534
  year: 2012
  end-page: 539
  ident: bib0078
  article-title: Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer
  publication-title: Hum Vaccin Immunother
  contributor:
    fullname: Hahn
– volume: 9
  start-page: 343
  year: 2010
  end-page: 349
  ident: bib0004
  article-title: Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
  publication-title: Cancer Biol Ther
  contributor:
    fullname: del Castillo Bahi
– volume: 13
  start-page: 295
  year: 2008
  end-page: 308
  ident: bib0056
  article-title: Cancer vaccines: on the threshold of success
  publication-title: Experd Opin Emerg Drugs
  contributor:
    fullname: Emens
– volume: 20
  start-page: 5
  year: 2006
  end-page: 13
  ident: bib0034
  article-title: Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events
  publication-title: Oncology (Williston Park)
  contributor:
    fullname: Lenz
– volume: 2
  start-page: 708
  year: 2014
  end-page: 713
  ident: bib0080
  article-title: Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic
  publication-title: Cancer Immunol Res
  contributor:
    fullname: Finn
– volume: 187
  start-page: 4954
  year: 2011
  end-page: 4966
  ident: bib0074
  article-title: Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody
  publication-title: J Immunol
  contributor:
    fullname: Sanchez
– volume: 7
  start-page: 77
  year: 2013
  end-page: 90
  ident: bib0037
  article-title: Cetuximab: its unique place in head and neck cancer treatment
  publication-title: Biologics
  contributor:
    fullname: Vermorken
– volume: 113
  start-page: 292
  year: 2017
  end-page: 303
  ident: bib0077
  article-title: A comprehensive review of immunotherapies in prostate cancer
  publication-title: Crit Rev Oncol Hematol
  contributor:
    fullname: Hansen
– volume: 1139
  start-page: 543
  year: 2014
  end-page: 553
  ident: bib0006
  article-title: Challenges facing the development of cancer vaccines
  publication-title: Methods Mol Biol
  contributor:
    fullname: Fishman
– volume: 6
  start-page: 18192
  year: 2015
  end-page: 18205
  ident: bib0093
  article-title: Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
  publication-title: Oncotarget
  contributor:
    fullname: Becht
– volume: 6
  start-page: 31740
  year: 2016
  ident: bib0105
  article-title: Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential
  publication-title: Sci Rep
  contributor:
    fullname: Popova
– volume: 365
  start-page: 1273
  year: 2011
  end-page: 1283
  ident: bib0050
  article-title: Adjuvant trastuzumab in HER2-positive breast cancer
  publication-title: N Engl J Med
  contributor:
    fullname: Robert
– volume: 26
  start-page: 342
  year: 2008
  end-page: 344
  ident: bib0061
  article-title: HER1 vaccine: an autologous EGFR vaccine candidate to treat epithelial tumors
  publication-title: Applied Biotechnol
  contributor:
    fullname: Hernández
– volume: 62
  start-page: 245
  year: 2013
  end-page: 256
  ident: bib0091
  article-title: T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment
  publication-title: Cancer Immunol Immunother
  contributor:
    fullname: Lougheed
– volume: 7
  start-page: 74362
  year: 2016
  end-page: 74379
  ident: bib0019
  article-title: Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma
  publication-title: Oncotarget
  contributor:
    fullname: Paielli
– volume: 7
  start-page: 10255
  year: 2017
  ident: bib0023
  article-title: PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis
  publication-title: Sci Rep
  contributor:
    fullname: Wang
– volume: 14
  start-page: 797
  year: 2008
  end-page: 803
  ident: bib0098
  article-title: Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
  publication-title: Clin Cancer Res
  contributor:
    fullname: Hueman
– volume: 25
  start-page: 1658
  year: 2007
  end-page: 1664
  ident: bib0047
  article-title: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
  publication-title: J Clin Oncol
  contributor:
    fullname: Siena
– volume: 10
  start-page: 2123
  year: 2014
  end-page: 2129
  ident: bib0088
  article-title: Active and passive immunization for cancer
  publication-title: Hum Vaccin Immunother
  contributor:
    fullname: Baxter
– volume: 8
  start-page: 382
  year: 2017
  ident: bib0036
  article-title: Nimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of EGFR-specific T cells in head and neck cancer patients
  publication-title: Front Pharmacol
  contributor:
    fullname: Concha-Benavente
– volume: 10
  start-page: 3332
  year: 2014
  end-page: 3346
  ident: bib0005
  article-title: Antigen-specific vaccines for cancer treatment
  publication-title: Hum Vaccin Immunother
  contributor:
    fullname: Buonaguro
– volume: 11
  start-page: 98
  year: 2014
  end-page: 103
  ident: bib0073
  article-title: Effects of an epidermal growth factor receptor-based cancer vaccine on wound healing and inflammation processes in murine experimental models
  publication-title: Int Wound J
  contributor:
    fullname: Casaco
– volume: 90
  start-page: 449
  year: 2004
  end-page: 454
  ident: bib0075
  article-title: Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence
  publication-title: Br J Cancer
  contributor:
    fullname: Nesland
– volume: 110
  start-page: 775
  year: 2002
  end-page: 787
  ident: bib0011
  article-title: Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains
  publication-title: Cell
  contributor:
    fullname: Nureki
– volume: 156
  start-page: 319
  year: 2016
  end-page: 330
  ident: bib0084
  article-title: A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
  publication-title: Breast Cancer Res Treat
  contributor:
    fullname: Dorval
– volume: 28
  start-page: 329
  year: 2016
  end-page: 338
  ident: bib0106
  article-title: Vaccine adjuvants as potential cancer immunotherapeutics
  publication-title: Int Immunol
  contributor:
    fullname: Ishii
– volume: 353
  start-page: 123
  year: 2005
  end-page: 132
  ident: bib0040
  article-title: Erlotinib in previously treated non-small-cell lung cancer
  publication-title: N Engl J Med
  contributor:
    fullname: Ciuleanu
– volume: 24
  start-page: 1740
  year: 2013
  end-page: 1748
  ident: bib0057
  article-title: Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives
  publication-title: Ann Oncol
  contributor:
    fullname: Valabrega
– volume: 5
  start-page: 520
  year: 2014
  ident: bib0087
  article-title: IgG subclasses and allotypes: from structure to effector functions
  publication-title: Front Immunol
  contributor:
    fullname: Rispens
– volume: 5
  start-page: 317
  year: 2004
  end-page: 328
  ident: bib0014
  article-title: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
  publication-title: Cancer Cell
  contributor:
    fullname: Vajdos
– volume: 1
  start-page: 77
  year: 2007
  end-page: 91
  ident: bib0038
  article-title: Cetuximab in the management of colorectal cancer
  publication-title: Biologics
  contributor:
    fullname: Lenz
– volume: 8
  start-page: 303
  year: 2003
  end-page: 306
  ident: bib0039
  article-title: FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets
  publication-title: Oncologist
  contributor:
    fullname: Pazdur
– volume: 277
  start-page: 46265
  year: 2002
  end-page: 46272
  ident: bib0008
  article-title: Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
  publication-title: J Biol Chem
  contributor:
    fullname: Eigenbrot
– volume: 19
  start-page: 1858
  year: 2013
  end-page: 1872
  ident: bib0035
  article-title: Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients
  publication-title: Clin Cancer Res
  contributor:
    fullname: Andrade Filho
– volume: 4
  start-page: 936
  year: 2016
  end-page: 947
  ident: bib0021
  article-title: Kinase regulation of human MHC class I molecule expression on cancer cells
  publication-title: Cancer Immunol Res
  contributor:
    fullname: Manchado
– volume: 4
  start-page: 1669
  year: 2007
  end-page: 1679
  ident: bib0066
  article-title: BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
  publication-title: PLoS Med
  contributor:
    fullname: Kumar
– volume: 7
  start-page: 505
  year: 2006
  end-page: 516
  ident: bib0009
  article-title: EGF-ERBB signalling: towards the systems level
  publication-title: Nat Rev Mol Cell Biol
  contributor:
    fullname: Yarden
– volume: 12
  start-page: 553
  year: 2012
  end-page: 563
  ident: bib0002
  article-title: The ERBB network: at last, cancer therapy meets systems biology
  publication-title: Nat Rev Cancer
  contributor:
    fullname: Pines
– volume: 8
  start-page: 595
  year: 2017
  ident: bib0054
  article-title: Upregulation of HLA class I expression on tumor cells by the anti-EGFR antibody nimotuzumab
  publication-title: Front Pharmacol
  contributor:
    fullname: Garrido
– volume: 15
  start-page: 1196
  year: 2013
  end-page: 1206
  ident: bib0070
  article-title: Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab
  publication-title: Neoplasia
  contributor:
    fullname: Starr
– volume: 421
  start-page: 756
  year: 2003
  end-page: 760
  ident: bib0013
  article-title: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
  publication-title: Nature
  contributor:
    fullname: Ramyar
– volume: 5
  start-page: 21
  year: 2005
  end-page: 23
  ident: bib0031
  article-title: Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer
  publication-title: Clin Colorectal Cancer
  contributor:
    fullname: Tyagi
– volume: 10
  start-page: 3251
  year: 2014
  end-page: 3260
  ident: bib0089
  article-title: Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination
  publication-title: Hum Vaccin Immunother
  contributor:
    fullname: Mesa
– volume: 4
  start-page: 259
  year: 2005
  end-page: 274
  ident: bib0090
  article-title: Vaccines in cancer: GVAX, a GM-CSF gene vaccine
  publication-title: Exp Rev Vaccine
  contributor:
    fullname: Nemunaitis
– volume: 22
  start-page: 3045
  year: 2004
  end-page: 3052
  ident: bib0060
  article-title: Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation
  publication-title: Vaccine
  contributor:
    fullname: Fernandez
– volume: 8
  start-page: 13
  year: 2017
  end-page: 19
  ident: bib0032
  article-title: Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
  publication-title: Lung Cancer
  contributor:
    fullname: Wozniak
– volume: 70
  start-page: 588
  year: 2010
  end-page: 597
  ident: bib0069
  article-title: Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy
  publication-title: Cancer Res
  contributor:
    fullname: Koefoed
– volume: 107
  start-page: 13252
  year: 2010
  end-page: 132587
  ident: bib0068
  article-title: Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
  publication-title: Proc Natl Acad Sci U S A
  contributor:
    fullname: Abramovitch
– volume: 9
  start-page: 263
  year: 2018
  end-page: 268
  ident: bib0107
  article-title: Cancer vaccine: learning lessons from immune checkpoint inhibitors
  publication-title: J Cancer
  contributor:
    fullname: Qian
– volume: 117
  start-page: 2051
  year: 2007
  end-page: 2058
  ident: bib0012
  article-title: ErbB receptors: from oncogenes to targeted cancer therapies
  publication-title: J Clin Invest
  contributor:
    fullname: Wang
– volume: 14
  start-page: 151
  year: 2012
  end-page: 157
  ident: bib0072
  article-title: Lentiviral vector followed by protein immunisation breaks tolerance against the self-antigen Her1 andresults in lung cancer immunotherapy
  publication-title: J Gene Med
  contributor:
    fullname: Arce
– volume: 20
  start-page: 92
  year: 2018
  end-page: 98
  ident: bib0026
  article-title: Navigating the "no man's land" of TKI-failed EGFR-mutated non-small cell lung cancer (NSCLC): a review
  publication-title: Neoplasia
  contributor:
    fullname: Reid
– volume: 6
  start-page: 18192
  year: 2015
  ident: 10.1053/j.seminoncol.2018.05.002_bib0093
  article-title: Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4145
  contributor:
    fullname: Podrazil
– volume: 2016
  year: 2016
  ident: 10.1053/j.seminoncol.2018.05.002_bib0045
  article-title: Vandetanib induces a marked anti-tumor effect and amelioration of ectopic Cushing's syndrome in a medullary thyroid carcinoma patient
  publication-title: Endocrinol Diabetes Metab Case Rep
  contributor:
    fullname: Bseiso
– volume: 32
  start-page: 2241
  year: 2014
  ident: 10.1053/j.seminoncol.2018.05.002_bib0100
  article-title: Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors
  publication-title: results of the CENTAURO antigen dose escalation phase I clinical trial. Vaccine
  contributor:
    fullname: Gavilondo
– volume: 20
  start-page: 92
  year: 2018
  ident: 10.1053/j.seminoncol.2018.05.002_bib0026
  article-title: Navigating the "no man's land" of TKI-failed EGFR-mutated non-small cell lung cancer (NSCLC): a review
  publication-title: Neoplasia
  doi: 10.1016/j.neo.2017.11.001
  contributor:
    fullname: Oronsky
– volume: 7
  start-page: 505
  year: 2006
  ident: 10.1053/j.seminoncol.2018.05.002_bib0009
  article-title: EGF-ERBB signalling: towards the systems level
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/nrm1962
  contributor:
    fullname: Citri
– volume: 6
  start-page: 31740
  year: 2016
  ident: 10.1053/j.seminoncol.2018.05.002_bib0105
  article-title: Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential
  publication-title: Sci Rep
  doi: 10.1038/srep31740
  contributor:
    fullname: Lohmueller
– volume: 5
  start-page: 456
  year: 2007
  ident: 10.1053/j.seminoncol.2018.05.002_bib0043
  article-title: Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer
  publication-title: Clin Adv Hematol Oncol
  contributor:
    fullname: Cameron
– volume: 10
  start-page: 1
  year: 2015
  ident: 10.1053/j.seminoncol.2018.05.002_bib0095
  article-title: Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy
  publication-title: Core Evidence
  contributor:
    fullname: Graff
– volume: 13
  start-page: 295
  year: 2008
  ident: 10.1053/j.seminoncol.2018.05.002_bib0056
  article-title: Cancer vaccines: on the threshold of success
  publication-title: Experd Opin Emerg Drugs
  doi: 10.1517/14728214.13.2.295
  contributor:
    fullname: Emens
– volume: 8
  start-page: 64600
  year: 2017
  ident: 10.1053/j.seminoncol.2018.05.002_bib0029
  article-title: Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.19925
  contributor:
    fullname: Dong
– volume: 4
  start-page: 1669
  year: 2007
  ident: 10.1053/j.seminoncol.2018.05.002_bib0066
  article-title: BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.0040315
  contributor:
    fullname: Costa
– volume: 14
  start-page: 151
  year: 2012
  ident: 10.1053/j.seminoncol.2018.05.002_bib0072
  article-title: Lentiviral vector followed by protein immunisation breaks tolerance against the self-antigen Her1 andresults in lung cancer immunotherapy
  publication-title: J Gene Med
  doi: 10.1002/jgm.2606
  contributor:
    fullname: Alpizar
– volume: 2
  start-page: 708
  year: 2014
  ident: 10.1053/j.seminoncol.2018.05.002_bib0080
  article-title: Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-14-0110
  contributor:
    fullname: Finn
– volume: 15
  start-page: 151
  year: 2010
  ident: 10.1053/j.seminoncol.2018.05.002_bib0022
  article-title: Growth factors in tumor microenvironment
  publication-title: Front Biosci
  doi: 10.2741/3612
  contributor:
    fullname: Zhang
– volume: 2
  start-page: 25
  year: 2010
  ident: 10.1053/j.seminoncol.2018.05.002_bib0081
  article-title: Progress in the development of a therapeutic vaccine for breast cancer
  publication-title: Breast Cancer
  contributor:
    fullname: Coveler
– volume: 3
  start-page: 71
  year: 1997
  ident: 10.1053/j.seminoncol.2018.05.002_bib0033
  article-title: Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity
  publication-title: Immunotechnology
  doi: 10.1016/S1380-2933(97)00065-1
  contributor:
    fullname: Mateo
– volume: 16
  start-page: 147
  year: 2016
  ident: 10.1053/j.seminoncol.2018.05.002_bib0041
  publication-title: BMC Cancer
  doi: 10.1186/s12885-016-2201-9
  contributor:
    fullname: Lee
– volume: 17
  start-page: 779
  year: 2017
  ident: 10.1053/j.seminoncol.2018.05.002_bib0028
  article-title: Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms
  publication-title: Exp Rev Anticancer Ther
  doi: 10.1080/14737140.2017.1355243
  contributor:
    fullname: Suda
– volume: 67
  start-page: 89
  year: 2018
  ident: 10.1053/j.seminoncol.2018.05.002_bib0094
  article-title: Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-017-2068-x
  contributor:
    fullname: Fucikova
– volume: 6
  start-page: 519
  year: 2014
  ident: 10.1053/j.seminoncol.2018.05.002_bib0096
  article-title: The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response
  publication-title: Immunotherapy
  doi: 10.2217/imt.14.22
  contributor:
    fullname: Schneble
– volume: 30
  start-page: 1138
  year: 2012
  ident: 10.1053/j.seminoncol.2018.05.002_bib0049
  article-title: Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
  publication-title: Invest New Drugs
  doi: 10.1007/s10637-010-9619-8
  contributor:
    fullname: Strumberg
– volume: 198
  start-page: 259
  year: 2004
  ident: 10.1053/j.seminoncol.2018.05.002_bib0067
  article-title: Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.10411
  contributor:
    fullname: Campiglio
– volume: 5
  start-page: 317
  year: 2004
  ident: 10.1053/j.seminoncol.2018.05.002_bib0014
  article-title: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
  publication-title: Cancer Cell
  doi: 10.1016/S1535-6108(04)00083-2
  contributor:
    fullname: Franklin
– volume: 284
  start-page: 54
  year: 2003
  ident: 10.1053/j.seminoncol.2018.05.002_bib0015
  article-title: The deaf and the dumb: the biology of ErbB-2 and ErbB-3
  publication-title: Exp Cell Res
  doi: 10.1016/S0014-4827(02)00101-5
  contributor:
    fullname: Citri
– volume: 107
  start-page: 13252
  year: 2010
  ident: 10.1053/j.seminoncol.2018.05.002_bib0068
  article-title: Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0913476107
  contributor:
    fullname: Spangler
– volume: 119
  start-page: 421
  year: 2013
  ident: 10.1053/j.seminoncol.2018.05.002_bib0055
  article-title: Therapeutic cancer vaccines: past, present, and future
  publication-title: Adv Cancer Res
  doi: 10.1016/B978-0-12-407190-2.00007-1
  contributor:
    fullname: Guo
– volume: 367
  start-page: 1783
  year: 2012
  ident: 10.1053/j.seminoncol.2018.05.002_bib0051
  article-title: Trastuzumab emtansine for HER2-positive advanced breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1209124
  contributor:
    fullname: Verma
– volume: 41
  start-page: 107
  year: 2005
  ident: 10.1053/j.seminoncol.2018.05.002_bib0030
  article-title: Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody
  publication-title: Drugs Today (Barc)
  doi: 10.1358/dot.2005.41.2.882662
  contributor:
    fullname: Harding
– volume: 156
  start-page: 319
  year: 2016
  ident: 10.1053/j.seminoncol.2018.05.002_bib0084
  article-title: A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-016-3751-x
  contributor:
    fullname: Limentani
– volume: 17
  start-page: 637
  year: 2017
  ident: 10.1053/j.seminoncol.2018.05.002_bib0027
  article-title: Understanding and targeting resistance mechanisms in NSCLC
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc.2017.84
  contributor:
    fullname: Rotow
– volume: 365
  start-page: 1273
  year: 2011
  ident: 10.1053/j.seminoncol.2018.05.002_bib0050
  article-title: Adjuvant trastuzumab in HER2-positive breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0910383
  contributor:
    fullname: Slamon
– volume: 12
  start-page: 159
  year: 2016
  ident: 10.1053/j.seminoncol.2018.05.002_bib0086
  article-title: Safety and tolerability evaluation of the use of Montanide ISA51 as vaccine adjuvant: a systematic review
  publication-title: Hum Vaccin Immunother
  doi: 10.1080/21645515.2015.1071455
  contributor:
    fullname: van Doorn E
– volume: 8
  start-page: 263
  year: 2017
  ident: 10.1053/j.seminoncol.2018.05.002_bib0058
  article-title: Safety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: a dose-escalation phase I study trial
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2017.00263
  contributor:
    fullname: Caballero
– volume: 6
  start-page: e15945
  year: 2011
  ident: 10.1053/j.seminoncol.2018.05.002_bib0010
  article-title: High- and low-affinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways
  publication-title: PloS One
  doi: 10.1371/journal.pone.0015945
  contributor:
    fullname: Krall
– volume: 378
  start-page: 113
  year: 2018
  ident: 10.1053/j.seminoncol.2018.05.002_bib0044
  article-title: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1713137
  contributor:
    fullname: Soria
– volume: 25
  start-page: 1658
  year: 2007
  ident: 10.1053/j.seminoncol.2018.05.002_bib0047
  article-title: Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2006.08.1620
  contributor:
    fullname: Van Cutsem E
– volume: 20
  start-page: 35
  issue: Suppl 2
  year: 2006
  ident: 10.1053/j.seminoncol.2018.05.002_bib0082
  article-title: Nondermatologic adverse events associated with anti-EGFR therapy
  publication-title: Oncology
  contributor:
    fullname: Sandler
– volume: 5
  start-page: 520
  year: 2014
  ident: 10.1053/j.seminoncol.2018.05.002_bib0087
  article-title: IgG subclasses and allotypes: from structure to effector functions
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2014.00520
  contributor:
    fullname: Vidarsson
– volume: 5
  start-page: 341
  year: 2005
  ident: 10.1053/j.seminoncol.2018.05.002_bib0001
  article-title: ERBB receptors and cancer: the complexity of targeted inhibitors
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc1609
  contributor:
    fullname: Hynes
– volume: 16
  start-page: 15
  year: 2012
  ident: 10.1053/j.seminoncol.2018.05.002_bib0003
  article-title: Targeting the EGFR signaling pathway in cancer therapy
  publication-title: Expert Opin Ther Targets
  doi: 10.1517/14728222.2011.648617
  contributor:
    fullname: Seshacharyulu
– volume: 9
  start-page: 263
  year: 2018
  ident: 10.1053/j.seminoncol.2018.05.002_bib0107
  article-title: Cancer vaccine: learning lessons from immune checkpoint inhibitors
  publication-title: J Cancer
  doi: 10.7150/jca.20059
  contributor:
    fullname: Ye
– volume: 363
  start-page: 411
  year: 2010
  ident: 10.1053/j.seminoncol.2018.05.002_bib0079
  article-title: Sipuleucel-T immunotherapy for castration-resistant prostate cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1001294
  contributor:
    fullname: Kantoff
– volume: 7
  start-page: 10255
  year: 2017
  ident: 10.1053/j.seminoncol.2018.05.002_bib0023
  article-title: PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis
  publication-title: Sci Rep
  doi: 10.1038/s41598-017-10925-7
  contributor:
    fullname: Zhang
– volume: 277
  start-page: 46265
  year: 2002
  ident: 10.1053/j.seminoncol.2018.05.002_bib0008
  article-title: Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M207135200
  contributor:
    fullname: Stamos
– volume: 353
  start-page: 123
  year: 2005
  ident: 10.1053/j.seminoncol.2018.05.002_bib0040
  article-title: Erlotinib in previously treated non-small-cell lung cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa050753
  contributor:
    fullname: Shepherd
– volume: 8
  start-page: 595
  year: 2017
  ident: 10.1053/j.seminoncol.2018.05.002_bib0054
  article-title: Upregulation of HLA class I expression on tumor cells by the anti-EGFR antibody nimotuzumab
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2017.00595
  contributor:
    fullname: Garrido
– volume: 10
  start-page: 2123
  year: 2014
  ident: 10.1053/j.seminoncol.2018.05.002_bib0088
  article-title: Active and passive immunization for cancer
  publication-title: Hum Vaccin Immunother
  doi: 10.4161/hv.29604
  contributor:
    fullname: Baxter
– volume: 119
  start-page: 2190
  year: 2006
  ident: 10.1053/j.seminoncol.2018.05.002_bib0059
  article-title: Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant
  publication-title: Int J Cancer
  doi: 10.1002/ijc.22085
  contributor:
    fullname: Sanchez-Ramırez
– volume: 31
  start-page: 89
  year: 2012
  ident: 10.1053/j.seminoncol.2018.05.002_bib0085
  article-title: Non-clinical immuno-toxicological evaluation of HER1 cancer vaccine in non-human primates: a 12-month study
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2012.10.098
  contributor:
    fullname: Bada Barro
– volume: 110
  start-page: 775
  year: 2002
  ident: 10.1053/j.seminoncol.2018.05.002_bib0011
  article-title: Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains
  publication-title: Cell
  doi: 10.1016/S0092-8674(02)00963-7
  contributor:
    fullname: Ogiso
– volume: 5
  start-page: 21
  year: 2005
  ident: 10.1053/j.seminoncol.2018.05.002_bib0031
  article-title: Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer
  publication-title: Clin Colorectal Cancer
  doi: 10.1016/S1533-0028(11)70161-X
  contributor:
    fullname: Tyagi
– volume: 57
  start-page: 1511
  year: 2008
  ident: 10.1053/j.seminoncol.2018.05.002_bib0097
  article-title: The E75 HER2/neu peptide vaccine
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-008-0540-3
  contributor:
    fullname: Mittendorf
– volume: 110
  start-page: 763
  year: 2002
  ident: 10.1053/j.seminoncol.2018.05.002_bib0063
  article-title: Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha
  publication-title: Cell
  doi: 10.1016/S0092-8674(02)00940-6
  contributor:
    fullname: Garrett
– volume: 7
  start-page: 77
  year: 2013
  ident: 10.1053/j.seminoncol.2018.05.002_bib0037
  article-title: Cetuximab: its unique place in head and neck cancer treatment
  publication-title: Biologics
  contributor:
    fullname: Specenier
– volume: 15
  start-page: 28
  year: 2004
  ident: 10.1053/j.seminoncol.2018.05.002_bib0018
  article-title: Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdh011
  contributor:
    fullname: Selvaggi
– volume: 8
  start-page: 3438
  year: 2002
  ident: 10.1053/j.seminoncol.2018.05.002_bib0020
  article-title: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer
  publication-title: Clin Cancer Res
  contributor:
    fullname: Di Lorenzo
– volume: 27
  start-page: 1573
  year: 2016
  ident: 10.1053/j.seminoncol.2018.05.002_bib0048
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdw214
  contributor:
    fullname: Paz-Ares
– volume: 28
  start-page: 329
  year: 2016
  ident: 10.1053/j.seminoncol.2018.05.002_bib0106
  article-title: Vaccine adjuvants as potential cancer immunotherapeutics
  publication-title: Int Immunol
  doi: 10.1093/intimm/dxw015
  contributor:
    fullname: Temizoz
– volume: 62
  start-page: 53
  year: 2007
  ident: 10.1053/j.seminoncol.2018.05.002_bib0024
  article-title: EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2006.12.008
  contributor:
    fullname: Dassonville
– volume: 15
  start-page: 1196
  year: 2013
  ident: 10.1053/j.seminoncol.2018.05.002_bib0070
  article-title: Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab
  publication-title: Neoplasia
  doi: 10.1593/neo.131584
  contributor:
    fullname: Iida
– volume: 22
  start-page: 3782
  year: 2016
  ident: 10.1053/j.seminoncol.2018.05.002_bib0099
  article-title: A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-0855
  contributor:
    fullname: Rodriguez
– volume: 4
  start-page: 936
  year: 2016
  ident: 10.1053/j.seminoncol.2018.05.002_bib0021
  article-title: Kinase regulation of human MHC class I molecule expression on cancer cells
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-16-0177
  contributor:
    fullname: Brea
– volume: 12
  start-page: 553
  year: 2012
  ident: 10.1053/j.seminoncol.2018.05.002_bib0002
  article-title: The ERBB network: at last, cancer therapy meets systems biology
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3309
  contributor:
    fullname: Yarden
– volume: 69
  start-page: 5089
  year: 2010
  ident: 10.1053/j.seminoncol.2018.05.002_bib0103
  article-title: Results of two phase I clinical trials of MVA-BN-HER2 in HER-2 overexpressing metastatic breast cancer patients
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.SABCS-09-5089
  contributor:
    fullname: Guardino
– volume: 65
  start-page: 226
  year: 2005
  ident: 10.1053/j.seminoncol.2018.05.002_bib0017
  article-title: Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.226.65.1
  contributor:
    fullname: Amann
– volume: 19
  start-page: 1858
  year: 2013
  ident: 10.1053/j.seminoncol.2018.05.002_bib0035
  article-title: Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-2426
  contributor:
    fullname: Srivastava
– volume: 10
  start-page: 3251
  year: 2014
  ident: 10.1053/j.seminoncol.2018.05.002_bib0089
  article-title: Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination
  publication-title: Hum Vaccin Immunother
  doi: 10.4161/hv.29847
  contributor:
    fullname: Fernández A
– volume: 117
  start-page: 2051
  year: 2007
  ident: 10.1053/j.seminoncol.2018.05.002_bib0012
  article-title: ErbB receptors: from oncogenes to targeted cancer therapies
  publication-title: J Clin Invest
  doi: 10.1172/JCI32278
  contributor:
    fullname: Zhang
– volume: 9
  start-page: 343
  year: 2010
  ident: 10.1053/j.seminoncol.2018.05.002_bib0004
  article-title: Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.9.5.10981
  contributor:
    fullname: Rodriguez
– volume: 375
  start-page: 11
  year: 2016
  ident: 10.1053/j.seminoncol.2018.05.002_bib0042
  article-title: Adaptive randomization of Neratinib in early breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1513750
  contributor:
    fullname: Park
– volume: 35
  start-page: 495
  year: 2007
  ident: 10.1053/j.seminoncol.2018.05.002_bib0065
  article-title: Apoptosis: a review of programmed cell death
  publication-title: Toxicol Pathol
  doi: 10.1080/01926230701320337
  contributor:
    fullname: Elmore
– volume: 90
  start-page: 449
  year: 2004
  ident: 10.1053/j.seminoncol.2018.05.002_bib0075
  article-title: Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6601536
  contributor:
    fullname: Hernes
– volume: 14
  start-page: 797
  year: 2008
  ident: 10.1053/j.seminoncol.2018.05.002_bib0098
  article-title: Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-1448
  contributor:
    fullname: Peoples
– volume: 22
  start-page: 3045
  year: 2004
  ident: 10.1053/j.seminoncol.2018.05.002_bib0060
  article-title: Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2004.02.010
  contributor:
    fullname: Mesa
– volume: 28
  start-page: 160
  year: 2009
  ident: 10.1053/j.seminoncol.2018.05.002_bib0071
  article-title: A matter of race: early-versus late-stage cancer diagnosis
  publication-title: Health Affairs
  doi: 10.1377/hlthaff.28.1.160
  contributor:
    fullname: Virnig
– volume: 62
  start-page: 245
  year: 2013
  ident: 10.1053/j.seminoncol.2018.05.002_bib0091
  article-title: T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment
  publication-title: Cancer Immunol Immunother
  doi: 10.1007/s00262-012-1330-5
  contributor:
    fullname: Santegoets
– volume: 20
  start-page: 5
  issue: Suppl 2
  year: 2006
  ident: 10.1053/j.seminoncol.2018.05.002_bib0034
  article-title: Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events
  publication-title: Oncology (Williston Park)
  contributor:
    fullname: Lenz
– volume: 8
  start-page: 13
  year: 2017
  ident: 10.1053/j.seminoncol.2018.05.002_bib0032
  article-title: Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
  publication-title: Lung Cancer
  contributor:
    fullname: Thakur
– volume: 187
  start-page: 4954
  year: 2011
  ident: 10.1053/j.seminoncol.2018.05.002_bib0074
  article-title: Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1003477
  contributor:
    fullname: Garrido
– volume: 8
  start-page: 303
  year: 2003
  ident: 10.1053/j.seminoncol.2018.05.002_bib0039
  article-title: FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets
  publication-title: Oncologist
  doi: 10.1634/theoncologist.8-4-303
  contributor:
    fullname: Cohen
– volume: 2
  start-page: 127
  year: 2001
  ident: 10.1053/j.seminoncol.2018.05.002_bib0007
  article-title: Untangling the ErbB signalling network
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/35052073
  contributor:
    fullname: Yarden
– volume: 3
  start-page: 25
  year: 2001
  ident: 10.1053/j.seminoncol.2018.05.002_bib0092
  article-title: Granulocyte macrophage colony-stimulating factor (GM-CSF) gene-transduced tumor vaccines (GVAX) in non-small-cell lung cancer
  publication-title: Clinical Lung Cancer
  doi: 10.1016/S1525-7304(11)70747-1
  contributor:
    fullname: Maung
– volume: 28
  start-page: 441
  year: 2017
  ident: 10.1053/j.seminoncol.2018.05.002_bib0104
  article-title: Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdx016
  contributor:
    fullname: Curigliano
– volume: 8
  start-page: 534
  year: 2012
  ident: 10.1053/j.seminoncol.2018.05.002_bib0078
  article-title: Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer
  publication-title: Hum Vaccin Immunother
  doi: 10.4161/hv.19795
  contributor:
    fullname: Gardner
– volume: 1
  start-page: 77
  year: 2007
  ident: 10.1053/j.seminoncol.2018.05.002_bib0038
  article-title: Cetuximab in the management of colorectal cancer
  publication-title: Biologics
  contributor:
    fullname: Lenz
– volume: 377
  start-page: 122
  year: 2017
  ident: 10.1053/j.seminoncol.2018.05.002_bib0052
  article-title: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1703643
  contributor:
    fullname: von Minckwitz
– volume: 113
  start-page: 292
  year: 2017
  ident: 10.1053/j.seminoncol.2018.05.002_bib0077
  article-title: A comprehensive review of immunotherapies in prostate cancer
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2017.02.026
  contributor:
    fullname: Maia
– volume: 421
  start-page: 756
  year: 2003
  ident: 10.1053/j.seminoncol.2018.05.002_bib0013
  article-title: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
  publication-title: Nature
  doi: 10.1038/nature01392
  contributor:
    fullname: Cho
– volume: 357
  start-page: 2040
  year: 2007
  ident: 10.1053/j.seminoncol.2018.05.002_bib0046
  article-title: Cetuximab for the treatment of colorectal cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa071834
  contributor:
    fullname: Jonker
– volume: 358
  start-page: 1160
  year: 2008
  ident: 10.1053/j.seminoncol.2018.05.002_bib0025
  article-title: EGFR antagonists in cancer treatment
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra0707704
  contributor:
    fullname: Ciardiello
– volume: 24
  start-page: 1740
  year: 2013
  ident: 10.1053/j.seminoncol.2018.05.002_bib0057
  article-title: Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives
  publication-title: Ann Oncol
  doi: 10.1093/annonc/mdt133
  contributor:
    fullname: Milani
– volume: 11
  start-page: 98
  year: 2014
  ident: 10.1053/j.seminoncol.2018.05.002_bib0073
  article-title: Effects of an epidermal growth factor receptor-based cancer vaccine on wound healing and inflammation processes in murine experimental models
  publication-title: Int Wound J
  doi: 10.1111/j.1742-481X.2012.01074.x
  contributor:
    fullname: Fuentes
– volume: 8
  start-page: 1156
  year: 2012
  ident: 10.1053/j.seminoncol.2018.05.002_bib0101
  article-title: Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer
  publication-title: Hum Vaccines Immunother
  doi: 10.4161/hv.20740
– volume: 1139
  start-page: 543
  year: 2014
  ident: 10.1053/j.seminoncol.2018.05.002_bib0006
  article-title: Challenges facing the development of cancer vaccines
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-4939-0345-0_39
  contributor:
    fullname: Fishman
– volume: 35
  start-page: 2949
  year: 2016
  ident: 10.1053/j.seminoncol.2018.05.002_bib0016
  article-title: The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors
  publication-title: Oncogene
  doi: 10.1038/onc.2015.372
  contributor:
    fullname: Schneider
– volume: 10
  start-page: 3332
  year: 2014
  ident: 10.1053/j.seminoncol.2018.05.002_bib0005
  article-title: Antigen-specific vaccines for cancer treatment
  publication-title: Hum Vaccin Immunother
  doi: 10.4161/21645515.2014.973317
  contributor:
    fullname: Tagliamonte
– volume: 14
  start-page: 840
  year: 2008
  ident: 10.1053/j.seminoncol.2018.05.002_bib0053
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-1050
  contributor:
    fullname: Garcia
– volume: 7
  start-page: 74362
  year: 2016
  ident: 10.1053/j.seminoncol.2018.05.002_bib0019
  article-title: Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.11413
  contributor:
    fullname: Bossi
– volume: 8
  start-page: 382
  year: 2017
  ident: 10.1053/j.seminoncol.2018.05.002_bib0036
  article-title: Nimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of EGFR-specific T cells in head and neck cancer patients
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2017.00382
  contributor:
    fullname: Mazorra
– volume: 26
  start-page: 4918
  year: 2008
  ident: 10.1053/j.seminoncol.2018.05.002_bib0062
  article-title: Anti-EGFR activation, anti-proliferative and pro-apoptotic effects of polyclonal antibodies induced by EGFR-based cancer vaccine
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2008.07.018
  contributor:
    fullname: Sánchez-Ramírez
– ident: 10.1053/j.seminoncol.2018.05.002_bib0076
  doi: 10.1002/cncr.21643
– volume: 16
  start-page: 228
  year: 2011
  ident: 10.1053/j.seminoncol.2018.05.002_bib0083
  article-title: Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2010-0298
  contributor:
    fullname: Pinto
– volume: 35
  start-page: 124
  year: 2017
  ident: 10.1053/j.seminoncol.2018.05.002_bib0102
  article-title: Revised overall survival analysis of a phase II, randomized, double-blind, controlled study of PROSTVAC in men with metastatic castration-resistant prostate cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.69.7748
  contributor:
    fullname: Kantoff
– volume: 26
  start-page: 342
  year: 2008
  ident: 10.1053/j.seminoncol.2018.05.002_bib0061
  article-title: HER1 vaccine: an autologous EGFR vaccine candidate to treat epithelial tumors
  publication-title: Applied Biotechnol
  contributor:
    fullname: Sánchez-Ramírez
– volume: 4
  start-page: 259
  year: 2005
  ident: 10.1053/j.seminoncol.2018.05.002_bib0090
  article-title: Vaccines in cancer: GVAX, a GM-CSF gene vaccine
  publication-title: Exp Rev Vaccine
  doi: 10.1586/14760584.4.3.259
  contributor:
    fullname: Nemunaitis
– volume: 70
  start-page: 588
  year: 2010
  ident: 10.1053/j.seminoncol.2018.05.002_bib0069
  article-title: Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-09-1417
  contributor:
    fullname: Pedersen
– volume: 7
  start-page: 301
  year: 2005
  ident: 10.1053/j.seminoncol.2018.05.002_bib0064
  article-title: Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2005.03.003
  contributor:
    fullname: Li
SSID ssj0021722
Score 2.3034177
SecondaryResourceType review_article
Snippet The human epidermal growth factor receptor 1 (HER1) is a tumor-associated antigen that has been validated as a clinical target for several passive, non-immune...
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 75
SubjectTerms cancer vaccine
HER1
immune response
Title HER1-based vaccine: Simultaneous activation of humoral and cellular immune response
URI https://dx.doi.org/10.1053/j.seminoncol.2018.05.002
https://www.ncbi.nlm.nih.gov/pubmed/30318087
https://search.proquest.com/docview/2120205969
Volume 45
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5FrYS4IN6ElxaJm-VgZ21nDacG2kaIckhaVHGx9okqlQRZSQ_5dfw0ZnbXdoIaUXpZxY683sx8mdfOzBLyliXWFpLnMYBFxZnlWcyZLWNrwHMzVlurMA558rWYnGWfz_PzXu_3RtbSaikHan1tXcltuAr3gK9YJfsfnG0nhRvwGfgLI3AYxhvxeHI4TWPUQzq6Egq3yNHBn11glqCYG8xuxbqFq84sXP10FfmumM1cXvocVCwRwdNTXLbsVmrQDFuPgOuLUZHFXG2F4Mem_iH0Ihq7vfbUR6KPaweDFnETU8_99xirjo62Lp28A3iKaDroIuPrRV1jeVRdG3cGUvRdXHTKYxYeh5esoymgGS8_1X6yMRbXhxBDiGSkfCOSEaRzyWLsyLcpnX2zyQaFoVTSC1t_5Eqjttm1CiFxp3pg_T7QyxEK0_n4wIfSOiXYbPz_pRvbjEW3V58z8JW6mSqcqUryynUz3R-CqAMZu388_vLtoHX609CMs_ltIZsM5nq3a1W7TKRdLpAzhU7vk3vBh6EHHpAPSM_MH5I7JyFL4xGZdbikAZfv6SYqaYdKurA0oJICKmmDSupRSRtUPiZnR4enHydxOLwjVtkwW8a6SDRPlRUKjNBc6iTXWqsSrEUGPuoI3HSmwXiUElx4GDMDrkOqRuXQaInpAOwJ2QPSmGeEjrjkQheK5yOWGa0FKxUTpkzVUEopTJ-kDb2qX75HS_UvfvXJh4awVbA1vQ1ZAXJu8PSbhhcViGMkjadfBZYgOGB5WZR98tQzqV0TQwWa8NHzW6z3Bbnb_WVekr1lvTKvwBxeytcBcX8AJju3ZA
link.rule.ids 315,783,787,27936,27937
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HER1-based+vaccine%3A+Simultaneous+activation+of+humoral+and+cellular+immune+response&rft.jtitle=Seminars+in+oncology&rft.au=Bergado+B%C3%A1ez%2C+Gretchen&rft.au=Hern%C3%A1ndez+Fern%C3%A1ndez%2C+Diana+R.&rft.au=Mazorra+Herrera%2C+Zaima&rft.au=S%C3%A1nchez+Ram%C3%ADrez%2C+Belinda&rft.date=2018-01-01&rft.issn=0093-7754&rft.volume=45&rft.issue=1-2&rft.spage=75&rft.epage=83&rft_id=info:doi/10.1053%2Fj.seminoncol.2018.05.002&rft.externalDBID=n%2Fa&rft.externalDocID=10_1053_j_seminoncol_2018_05_002
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0093-7754&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0093-7754&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0093-7754&client=summon